Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma [1]

British Journal of Haematology

Volumn 129, Issue 5, 2005, Pages 706-707

  Depil, Stéphane ^a   Mathiot, Claire ^b   Leleu, Xavier ^a   Moreau, Anne Sophie ^a   Faucompré, Jean Luc ^a   Hennache, Bernadette ^a   Bauters, Francis ^a   Bataille, Régis ^c   Facon, Thierry ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSTITUT CURIE   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Multiple myeloma; Osteoprotegerin; Prognosis

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; BONE LESION; CANCER SURVIVAL; CELL SECRETION; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EVALUATION; FEMALE; FOLLOW UP; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OSTEOCLAST; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS;

BIOLOGICAL MARKERS; GLYCOPROTEINS; HUMANS; MULTIPLE MYELOMA; OSTEOPROTEGERIN; PROGNOSIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; SURVIVAL RATE;

EID: 20444462771     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05518.x     Document Type: Letter

References (8)

1. Corso, A., Dovio, A., Rusconi, C., Sartori, M.L., Klersy, C., Varettoni, M., Mangiacavalli, S., Zappasodi, P., Ventura, M., Angeli, A. & Lazzarino, M. (2004) Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls. Leukemia, 18, 1555-1557.
2. Holen, I., Croucher, P.I., Hamdy, F.C. & Eaton, C.L. (2002) Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Research, 62, 1619-1623.
3. Kraj, M., Centkowski, P. & Kruk, B. (2003) Osteoprotegerin sRANKL serum levels in multiple myeloma patients (abstract 156). The Hematology Journal, 4 (Suppl. 1), S157.
4. Kyrtsonis, M.C., Vassilakopoulos, T.P., Papadogiannis, A., Tzenou, T., Dimopoulou, M.N., Siakantaris, M.P., Kokoris, S.I., Dimitriadou, E.M., Anagyrou, K. & Pangalis, G.A. (2004) OPG and sRANKL in serum of untreated multiple myeloma patients (abstract 047). The Hematology Journal, 5, S17.
5. Lipton, A., Ali, S.M., Leitzel, K., Chinchilli, V., Witters, L., Engle, L., Holloway, D., Bekker, P. & Dunstan, C.R. (2002) Serum osteoprotegerin levels in healthy controls and cancer patients. Clinical Cancer Research, 8, 2306-2310.
6. Seidel, C., Hjertner, O., Abildgaard, N., Heickendorff, L., Hjorth, M., Westin, J., Nielsen, J.L., Hjorth-Hansen, H., Waage, A., Sundan, A. & Borset, M. (2001) Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood, 98, 2269-2271.
7. Shipman, C.M. & Croucher, P.I. (2003) Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Research, 63, 912-916.
8. Terpos, E., Szydlo, R., Apperley, J.F., Hatjiharissi, E., Politou, M., Meletis, J., Viniou, N., Yataganas, X., Goldman, J.M. & Rahemtulla, A. (2003) Soluble receptor activator of nuclear factor kappaB ligand- osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood, 102, 1064-1069.